AbbVie's new Parkinson's drug DUOPA™ (carbidopa and levodopa) was recently approved by the FDA and is delivered straight into the patient's small intestine over a 16 hour period using an infusion pump and procedurally placed tube.
"The FDA approval of Duopa is another significant milestone for AbbVie's pipeline," AbbVie Chief Scientific Officer Dr. Michael Severino said in a statement. "This advancement is important for patients with advanced Parkinson's disease and their care teams, as it provides a new therapeutic option to help manage motor symptoms."
The oral delivery of levodopa/carbidopa is notorious for unpredictable absorption and this set off the search for new delivery methods - hence DUOPA and its percutaneous endoscopic gastrostomy procedure with jejunal extension, that delivers the drug into the small intestine by bypassing the stomach.
However, this approval is coming off the heels of the FDA approval of Impax Laboratories' RYTARY which contains both immediate and extended release beads of carbidopa and levodopa. Learn more about RYTARY here.
The drug delivery landscape is constantly evolving, don't get left behind! Join us at Drug Delivery Partnerships 2015 in Boca Raton, FL. Accelerate your path to market by leveraging new partnerships, breakthrough innovation and unique business models.
Download the agenda.
Register by Friday 1/16 and SAVE $300! Use the code XP2078BLOG to save.
No comments:
Post a Comment